BRIDGE PHARMA Trademark

Trademark Overview

On Wednesday, January 18, 2023, a trademark application was filed for BRIDGE PHARMA with the United States Patent and Trademark Office. The USPTO has given the BRIDGE PHARMA trademark a serial number of 97759618. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Tuesday, September 10, 2024. This trademark is owned by Bridgewest International Holdings LLC. The BRIDGE PHARMA trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Scientific research and development of therapeutics, disinfectants, diluents, and vaccines for the treatment of dehydrations, low potassium levels, bleeding, infection and pain
bridge pharma

General Information

Serial Number97759618
Word MarkBRIDGE PHARMA
Filing DateWednesday, January 18, 2023
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateTuesday, September 10, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

NOT AVAILABLE"PHARMA"
Goods and ServicesScientific research and development of therapeutics, disinfectants, diluents, and vaccines for the treatment of dehydrations, low potassium levels, bleeding, infection and pain

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, January 25, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBridgewest International Holdings LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressMiami, FL 33131

Trademark Events

Event DateEvent Description
Saturday, January 21, 2023NEW APPLICATION ENTERED
Wednesday, January 25, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, October 16, 2023ASSIGNED TO EXAMINER
Wednesday, October 25, 2023NON-FINAL ACTION WRITTEN
Wednesday, October 25, 2023NON-FINAL ACTION E-MAILED
Wednesday, October 25, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, January 24, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, January 24, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, January 25, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, March 7, 2024FINAL REFUSAL WRITTEN
Thursday, March 7, 2024FINAL REFUSAL E-MAILED
Thursday, March 7, 2024NOTIFICATION OF FINAL REFUSAL EMAILED
Tuesday, May 14, 2024DIVISIONAL REQUEST RECEIVED
Tuesday, May 14, 2024TEAS REQUEST TO DIVIDE RECEIVED
Friday, June 7, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Friday, June 7, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Tuesday, August 6, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, August 7, 2024DIVISIONAL PROCESSING COMPLETE
Wednesday, August 7, 2024ATTORNEY REVIEW COMPLETED
Tuesday, September 10, 2024ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Tuesday, September 10, 2024ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Wednesday, August 7, 2024REVIEW OF CORRESPONDENCE COMPLETE

Related Keywords

pharma bridge potassium dehydrations levels bleeding pain infection treatment vaccines development research